Please use this identifier to cite or link to this item:
https://doi.org/10.1101/gr.154492.113
Title: | Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma | Authors: | Kan, Z. Zheng, H. Liu, X. Li, S. Barber, T.D. Gong, Z. Gao, H. Hao, K. Willard, M.D. Xu, J. Hauptschein, R. Rejto, P.A. Fernandez, J. Wang, G. Zhang, Q. Wang, B. Chen, R. Wang, J. Lee, N.P. Zhou, W. Lin, Z. Peng, Z. Yi, K. Chen, S. Li, L. Fan, X. Yang, J. Ye, R. Ju, J. Wang, K. Estrella, H. Deng, S. Wei, P. Qiu, M. Wulur, I.H. Liu, J. Ehsani, M.E. Zhang, C. Loboda, A. Sung, W.K. Aggarwal, A. Poon, R.T. Fan, S.T. Wang, J. Hardwick, J. Reinhard, C. Dai, H. Li, Y. Luk, J.M. Mao, M. |
Issue Date: | Sep-2013 | Citation: | Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T.D., Gong, Z., Gao, H., Hao, K., Willard, M.D., Xu, J., Hauptschein, R., Rejto, P.A., Fernandez, J., Wang, G., Zhang, Q., Wang, B., Chen, R., Wang, J., Lee, N.P., Zhou, W., Lin, Z., Peng, Z., Yi, K., Chen, S., Li, L., Fan, X., Yang, J., Ye, R., Ju, J., Wang, K., Estrella, H., Deng, S., Wei, P., Qiu, M., Wulur, I.H., Liu, J., Ehsani, M.E., Zhang, C., Loboda, A., Sung, W.K., Aggarwal, A., Poon, R.T., Fan, S.T., Wang, J., Hardwick, J., Reinhard, C., Dai, H., Li, Y., Luk, J.M., Mao, M. (2013-09). Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research 23 (9) : 1422-1433. ScholarBank@NUS Repository. https://doi.org/10.1101/gr.154492.113 | Abstract: | Hepatocellular carcinoma (HCC) is one of the most deadly cancers worldwide and has no effective treatment, yet the molecular basis of hepatocarcinogenesis remains largely unknown. Here we report findings from a whole-genome sequencing (WGS) study of 88 matched HCC tumor/normal pairs, 81 of which are Hepatitis B virus (HBV) positive, seeking to identify genetically altered genes and pathways implicated in HBV-associated HCC. We find beta-catenin to be the most frequently mutated oncogene (15.9%) and TP53 the most frequently mutated tumor suppressor (35.2%). TheWnt/beta-catenin and JAK/STAT pathways, altered in 62.5% and 45.5% of cases, respectively, are likely to act as two major oncogenic drivers in HCC. This study also identifies several prevalent and potentially actionable mutations, including activating mutations of Janus kinase 1 ( JAK1), in 9.1% of patients and provides a path toward therapeutic intervention of the disease. © 2013, Published by Cold Spring Harbor Laboratory Press. | Source Title: | Genome Research | URI: | http://scholarbank.nus.edu.sg/handle/10635/77946 | ISSN: | 10889051 | DOI: | 10.1101/gr.154492.113 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.